NanoCarrier Co., Ltd. (JP:4571)
:4571
Want to see JP:4571 full AI Analyst Report?
4571 Stock Chart & Stats
¥134.00
-¥1.00(-0.68%)
At close: 4:00 PM EST
¥134.00
-¥1.00(-0.68%)
Day’s Range― - ―
52-Week Range¥100.00 - ¥254.00
Previous CloseN/A
Volume236.30K
Average Volume (3M)2.35M
Market Cap
¥8.49B
Enterprise Value¥6.37B
Total Cash (Recent Filing)¥3.40B
Total Debt (Recent Filing)¥540.24M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.48
Shares Outstanding83,221,756
10 Day Avg. Volume484,410
30 Day Avg. Volume2,345,523
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary DDS PlatformNanoCarrier’s proprietary micellar nanoparticle DDS platform constitutes a durable technological moat that supports a licensing and collaboration business model. As a core IP asset it raises partner switching costs, enables milestone/royalty economics, and underpins recurring long-term revenue potential from therapeutics delivery.
High Gross MarginsSustained gross margins in the 72%–88% range indicate strong underlying product economics and efficient cost of goods. High gross margins provide structural capacity to fund R&D and partner programs from revenue as scale improves, improving the likelihood of transitioning toward profitability once fixed costs moderate.
Revenue ReboundA 50% year-over-year revenue rebound in 2026 suggests meaningful renewed partner activity or commercial traction for the DDS platform. Durable top-line recovery reduces dependence on financing, increases prospects for milestone and royalty income, and strengthens the pathway to sustainable operations over the medium term.
Bears Say
Negative Operating Cash FlowConsistent negative operating cash flow shows the core business consumes cash rather than generating it. This structural cash burn necessitates ongoing external financing, raising dilution or leverage risk and constraining the company’s ability to self-fund clinical development, commercialization or strategic investments over the coming months.
Rising Debt And Weakening Balance SheetAn increase in total debt to 1.6B alongside declining assets and equity reduces financial flexibility. Growing leverage combined with persistently negative returns on equity limits strategic options, increases interest burden risk, and can weaken negotiating power with partners or investors during crucial development milestones.
Persistent LossesDespite revenue improvement, the company records deep, persistent operating and net losses with highly negative margins. Continued unprofitability erodes retained earnings and increases dependence on milestone payments and external capital, making the path to self-sustaining profitability uncertain without material scale or new high-value partnerships.
NanoCarrier Co., Ltd. News
4571 FAQ
What was NanoCarrier Co., Ltd.’s price range in the past 12 months?
NanoCarrier Co., Ltd. lowest stock price was ¥100.00 and its highest was ¥254.00 in the past 12 months.
What is NanoCarrier Co., Ltd.’s market cap?
NanoCarrier Co., Ltd.’s market cap is ¥8.49B.
When is NanoCarrier Co., Ltd.’s upcoming earnings report date?
NanoCarrier Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were NanoCarrier Co., Ltd.’s earnings last quarter?
NanoCarrier Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥3.84 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.84.
Is NanoCarrier Co., Ltd. overvalued?
According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued.
Does NanoCarrier Co., Ltd. pay dividends?
NanoCarrier Co., Ltd. does not currently pay dividends.
What is NanoCarrier Co., Ltd.’s EPS estimate?
NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoCarrier Co., Ltd. have?
NanoCarrier Co., Ltd. has 83,221,756 shares outstanding.
What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?
NanoCarrier Co., Ltd. reported an EPS of -¥3.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4571
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoCarrier Co., Ltd.
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.
Technical Analysis
AnGes
―
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
STELLA PHARMA CORPORATION
―